The FDA Wants to Review Your Factory Before You Even Build It

Phase 2 (Application Submission) then builds on that foundation. By the time a company actually files its drug application, most of the manufacturing questions have already been addressed. The pre-approval inspection becomes a confirmation, not a surprise audit.

Importantly, PreCheck doesn't lower any standards. GMP requirements, quality benchmarks, and CMC (chemistry, manufacturing, and controls) expectations remain identical. The program just moves the conversation earlier, like studying for the test all semester instead of cramming the night before.

Who Made the Cut (and Why It Matters)

The seven selections tell a story about what the FDA considers strategically important right now.

Eli Lilly is bringing its Lebanon, Indiana facility into the program. That site will manufacture key ingredients for its weight-loss pills and injections, the hottest drug category on the planet. Lilly has poured over $21 billion into Indiana manufacturing since 2020 alone, and the Lebanon complex is on track to become the largest API production plant in the United States.

Regeneron enrolled its Saratoga Springs, New York site, part of a massive biologics expansion that includes over one million square feet of new property and roughly $2 billion in investment. Combined with a separate $3 billion deal with FUJIFILM Diosynth in North Carolina, Regeneron is working to nearly double its U.S. large-scale biologics manufacturing capacity.

The rest of the cohort adds diversity. Cellares works on automated cell therapy manufacturing. Kriya Therapeutics focuses on gene therapy. Kyowa Kirin and FUJIFILM Biotechnologies bring specialized biologics expertise. Amneal adds a generics perspective. Together, the seven represent the full spectrum of modern pharmaceutical manufacturing.

The Bigger Picture: Why Now?

PreCheck didn't emerge from a vacuum. It's a direct response to Executive Order 14293, which directed the FDA to streamline reviews of domestic pharmaceutical manufacturing and reduce reliance on foreign supply chains.

The timing makes sense. Demand for complex therapies (biologics, cell and gene therapies, GLP-1 drugs) is surging. Meanwhile, the U.S. remains uncomfortably dependent on overseas factories for critical medicines and active pharmaceutical ingredients. COVID exposed the fragility of that arrangement; tariff threats have only intensified the urgency.

The FDA is building a whole toolkit around this problem. A separate Commissioner's National Priority Review Voucher program has slashed certain review timelines to roughly 54 days, down from six to ten months. A domestic generics pilot encourages U.S.-made generics with American-sourced ingredients. And proposed 2026 legislation would require drug labels to identify the original manufacturer of every active ingredient, creating unprecedented supply chain transparency.

PreCheck is the manufacturing piece of that puzzle. Faster reviews don't help much if the factory isn't ready.

The Fine Print

Not everything is rosy. The initial cohort is just seven companies; that's a proof of concept, not an industry transformation. Scaling PreCheck to dozens or hundreds of facilities will require FDA resources that may not materialize quickly.

There's also a cautionary tale. The National Priority Review Voucher program, another acceleration initiative, has already seen two reviews delayed over safety and efficacy concerns. Faster doesn't always mean smoother.

Regulatory experts emphasize that the biggest benefit isn't raw speed; it's predictability. Companies investing billions in new facilities can now get early feedback on whether their designs will pass muster, rather than gambling on a high-stakes inspection years down the road. For smaller biotechs with limited cash runways, that certainty could be the difference between building domestically and outsourcing overseas.

What Comes Next

The FDA has said this first cohort is a learning exercise. Lessons from Lilly, Regeneron, and the other five will shape future rounds, though no timeline for the next class has been announced.

For now, seven construction sites across the country just became the most closely watched factories in pharma. The bulldozers are running, and for the first time, the FDA is riding shotgun.

Vistagen's Anxiety Drug Just Went 1-for-3 in Phase 3. Now What?

Vistagen's anxiety drug fasedienol just went 1-for-3 in Phase 3 trials, torching 80% of the stock's value. The company is betting a post-hoc subgroup signal and an FDA meeting can save a program that Wall Street has all but written off.